Literature DB >> 29926149

[Reply to: PSA screening : Possible uses and harm by N. Keller, M. Jenny, G. Gigerenzer, R. Ablin].

Carsten Stephan1,2, Thorsten Schlomm3, Klaus Jung3,4.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29926149     DOI： 10.1007/s00120-018-0697-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  13 in total

1.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

Authors:  Stacy Loeb; Edward F Vonesh; E Jeffrey Metter; H Ballentine Carter; Peter H Gann; William J Catalona
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

Review 2.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

3.  Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions.

Authors:  Monique J Roobol; Sigrid Carlsson; Jonas Hugosson
Journal:  Evid Based Med       Date:  2011-01-12

4.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  David C Grossman; Susan J Curry; Douglas K Owens; Kirsten Bibbins-Domingo; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; Mark Ebell; John W Epling; Alex R Kemper; Alex H Krist; Martha Kubik; C Seth Landefeld; Carol M Mangione; Michael Silverstein; Melissa A Simon; Albert L Siu; Chien-Wen Tseng
Journal:  JAMA       Date:  2018-05-08       Impact factor: 56.272

5.  Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Authors:  Monique J Roobol; Melissa Kerkhof; Fritz H Schröder; Jack Cuzick; Peter Sasieni; Matti Hakama; Ulf Hakan Stenman; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis Denis; Franz Recker; Antonio Berenguer; Mirja Ruutu; Paula Kujala; Chris H Bangma; Gunnar Aus; Teuvo L J Tammela; Arnauld Villers; Xavier Rebillard; Sue M Moss; Harry J de Koning; Jonas Hugosson; Anssi Auvinen
Journal:  Eur Urol       Date:  2009-07-28       Impact factor: 20.096

6.  [Detection of prostate cancer by real-time MR/ultrasound fusion-guided biopsy: 3T MRI and state of the art sonography].

Authors:  T Durmus; C Stephan; M Grigoryev; G Diederichs; M Saleh; T Slowinski; A Maxeiner; A Thomas; T Fischer
Journal:  Rofo       Date:  2013-02-18

7.  Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.

Authors:  Joshua A Halpern; Clara Oromendia; Jonathan E Shoag; Sameer Mittal; Michael F Cosiano; Karla V Ballman; Andrew J Vickers; Jim C Hu
Journal:  J Urol       Date:  2017-10-20       Impact factor: 7.450

8.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

9.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Authors:  Alex Tsodikov; Roman Gulati; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2018-04-17       Impact factor: 25.391

10.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.